<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">23961</article-id><article-id pub-id-type="doi">10.7554/eLife.23961</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Biophysics and Structural Biology</subject></subj-group></article-categories><title-group><article-title>Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-37807"><name><surname>Fung</surname><given-names>Ho Yee Joyce</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0502-1957</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataro1"/><xref ref-type="other" rid="dataro2"/><xref ref-type="other" rid="dataro3"/><xref ref-type="other" rid="dataro4"/></contrib><contrib contrib-type="author" id="author-38431"><name><surname>Fu</surname><given-names>Szu-Chin</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-1789"><name><surname>Chook</surname><given-names>Yuh Min</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4974-0726</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataro1"/><xref ref-type="other" rid="dataro2"/><xref ref-type="other" rid="dataro3"/><xref ref-type="other" rid="dataro4"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of Texas Southwestern Medical Center</institution>, <addr-line><named-content content-type="city">Dallas</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Mingjie</given-names></name><role>Reviewing editor</role><aff id="aff2"><institution>The Hong Kong University of Science and Technology</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>yuhmin.chook@utsouthwestern.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>03</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>e23961</elocation-id><history><date date-type="received"><day>06</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>03</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Fung et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Fung et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-23961-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.10034"/><abstract><object-id pub-id-type="doi">10.7554/eLife.23961.001</object-id><p>Nuclear export receptor CRM1 binds highly variable nuclear export signals (NESs) in hundreds of different cargoes. Previously we have shown that CRM1 binds NESs in both polypeptide orientations (Fung et al., 2015). Here, we show crystal structures of CRM1 bound to eight additional NESs which reveal diverse conformations that range from loop-like to all-helix, which occupy different extents of the invariant NES-binding groove. Analysis of all NES structures show 5-6 distinct backbone conformations where the only conserved secondary structural element is one turn of helix that binds the central portion of the CRM1 groove. All NESs also participate in main chain hydrogen bonding with human CRM1 Lys568 side chain, which acts as a specificity filter that prevents binding of non-NES peptides. The large conformational range of NES backbones explains the lack of a fixed pattern for its 3-5 hydrophobic anchor residues, which in turn explains the large array of peptide sequences that can function as NESs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.001">http://dx.doi.org/10.7554/eLife.23961.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>Exportin-1</kwd><kwd>XPO1</kwd><kwd>nuclear transport</kwd><kwd>NES</kwd><kwd>nuclear export signal</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd><italic>S. cerevisiae</italic></kwd><kwd>Human</kwd><kwd>Virus</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>International Student Research fellow</award-id><principal-award-recipient><name><surname>Fung</surname><given-names>Ho Yee Joyce</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001692</institution-id><institution>Croucher Foundation</institution></institution-wrap></funding-source><award-id>Graduate Student Scholarship</award-id><principal-award-recipient><name><surname>Fung</surname><given-names>Ho Yee Joyce</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP120352</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP150053</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 GM069909</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>I-1532</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005189</institution-id><institution>Leukemia and Lymphoma Society</institution></institution-wrap></funding-source><award-id>Scholar Award</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007914</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap></funding-source><award-id>Endowed Scholars Program</award-id><principal-award-recipient><name><surname>Chook</surname><given-names>Yuh Min</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Building on previous work (Fung et al., 2015), the structures of eight new nuclear export signal (NES) peptides bound to Exportin CRM1 are reported, revealing striking diversity in NES structures, a small conserved secondary structural element, and a CRM1 residue that functions as a selectivity filter.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The chromosome region maintenance 1 protein (CRM1) or Exportin-1 (XPO1) binds 8–15 residues-long nuclear export signals (NESs) in hundreds of different protein cargoes (<xref ref-type="bibr" rid="bib10">Fornerod et al., 1997</xref>; <xref ref-type="bibr" rid="bib12">Fukuda et al., 1997</xref>; <xref ref-type="bibr" rid="bib38">Stade et al., 1997</xref>; <xref ref-type="bibr" rid="bib30">Ossareh-Nazari et al., 1997</xref>; <xref ref-type="bibr" rid="bib49">Xu et al., 2012a</xref>; <xref ref-type="bibr" rid="bib20">Kırlı et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Thakar et al., 2013</xref>). NES sequences are very diverse but each usually has 4–5 hydrophobic residues (often Leu/Val/Ile/Phe/Met; labeled Ф0–5) that bind hydrophobic pockets (labeled P0–P4) in a hydrophobic groove formed by HEAT repeats 11 and 12 of CRM1 (9–16). The hydrophobic anchor residues are arranged in many ways, currently described by ten consensus patterns for corresponding NES classes 1a, 1b, 1c, 1d, 2, 3, 1a-R, 1b-R, 1c-R and 1d-R (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) (<xref ref-type="bibr" rid="bib13">Fung et al., 2015</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.23961.002</object-id><label>Figure 1.</label><caption><title>Structures of CRM1-bound NESs that match the potentially all-helical class 3 pattern.</title><p>(<bold>A</bold>) Current NES sequence patterns (Φ is Leu, Val, Ile, Phe or Met and X is any amino acid). Potential amphipathic α-helices, predicted with hydrophobic patterns of <italic>i</italic>, <italic>i</italic> + 4, <italic>i</italic> + 7 or <italic>i</italic>, <italic>i</italic> + 3, <italic>i</italic> + 7 or <italic>i</italic>, <italic>i</italic> + 3, <italic>i</italic> + 7, <italic>i</italic> + 10, are shaded grey. (<bold>B</bold>) Structure of PKI<sup>NES</sup>(Ф0L) (dark blue, PDB ID: 3NBY), Rev<sup>NES</sup> (pink, 3NBZ) and CPEB4<sup>NES</sup> (yellow, 5DIF) bound to the NES-binding groove of CRM1 (grey surface). NESs are shown in cartoon representations with their Φ side chains shown as sticks. (<bold>C</bold>) The overall structure of the engineered <italic><sup>Sc</sup></italic>CRM1 (grey)-Ran•GTP (orange)-RanBP1 (purple)-mDia2<sup>NES</sup> (pale green) complex. The structure of (<bold>D</bold>) mDia2<sup>NES</sup> (pale green), (<bold>E</bold>) CDC7<sup>NES</sup> (green-cyan) and (<bold>F</bold>) X11L2<sup>NES</sup> (forest) bound to the NES-binding groove of <italic><sup>Sc</sup></italic>CRM1 in the engineered <italic><sup>Sc</sup></italic>CRM1-Ran-RanBP1 complex. *The X11L2<sup>NES</sup> sequence matches the class 3 pattern, but binds CRM1 according to the new hydrophobic pattern Φ0XXΦ1XXXΦ2XXΦ3XXXΦ4 that we termed the class 4 pattern. mDia2<sup>NES</sup> is not shown in the leftmost panel of (<bold>D</bold>) to view the five hydrophobic pockets (<bold>P0–P4</bold>) of the CRM1 groove. Rightmost panels of (<bold>D–F</bold>): overlays of 3.0σ positive densities of kick OMIT mFo-DFc maps (calculated with peptides omitted) and final coordinates of the NES peptides. Middle panels of (<bold>D–F</bold>): black dashes show CRM1-NES hydrogen bonds and polar contacts.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.002">http://dx.doi.org/10.7554/eLife.23961.002</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.23961.003</object-id><label>Figure 1—source data 1.</label><caption><title>Data collection and refinement statistics.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.003">http://dx.doi.org/10.7554/eLife.23961.003</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-23961-fig1-data1-v2.docx"/></supplementary-material></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.23961.004</object-id><label>Figure 1—source data 2.</label><caption><title>Data collection and refinement statistics (cont.).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.004">http://dx.doi.org/10.7554/eLife.23961.004</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-23961-fig1-data2-v2.docx"/></supplementary-material></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.23961.005</object-id><label>Figure 1—source data 3.</label><caption><title>Crystallization conditions of CRM1-NES complexes.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.005">http://dx.doi.org/10.7554/eLife.23961.005</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-23961-fig1-data3-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.006</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Binding affinities of NES to CRM1 measured by differential bleaching experiments.</title><p>Data from triplicate experiments of direct (titration of CRM1 to FITC-PKI<sup>NES</sup> in the presence of excess RanGTP) or competition titrations (titration of MBP-NES to FITC-PKI<sup>NES</sup> and CRM1 with excess RanGTP) are plotted as mean ± SD and fitted binding curves are overlaid on top. MBP-NES competes with FITC-PKI<sup>NES</sup> for CRM1. Residuals are plotted at the bottom. Dissociation constants are reported below the graphs with ranges in brackets representing the 68.3% confidence interval. *Experiments done on different days were fitted using a corresponding triplicate set of direct titrations (traces in black).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.006">http://dx.doi.org/10.7554/eLife.23961.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp1-v2"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.007</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Modeling strategy for NESs with weak Φ side chain densities.</title><p>(<bold>A</bold>) The difference densities (mFo-DFc contoured at 2.5σ) for mDia2<sup>NES</sup> when the dataset was refined without the NES peptide. White circle on the left panel shows good side chain density for an arginine side chain. The image in the right panel shows the structure rotated 90 degrees to show strong side chain density for a hydrophobic residue pointing into the P2 pocket of CRM1. (<bold>B</bold>) Left panels: difference densities (mFo-DFc contoured at 3.0σ; shown in dashed white circles) for the incorrect model of FMRP-1b<sup>NES</sup>. Right panels: difference densities (mFo-DFc contoured at 3.0σ) for the correct model of FMRP-1b<sup>NES</sup> are shown at the same positions as the left panels. The absence of difference densities at side chain positions provides support for assignment of <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> to the NES peptide structure.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.007">http://dx.doi.org/10.7554/eLife.23961.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp2-v2"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.008</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Mutagenesis of FMRP-1b<sup>NES</sup> to validate the sequence assignment of the NES.</title><p>Differential bleaching experiments of FMRP-<sup>1b</sup>NES mutant YLKEVDQLRALER show that it does not bind CRM1, thus providing support that assignment of <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> to the FMRP-1b<sup>NES</sup> is most likely correct. Triplicate direct tirations of CRM1 into FITC-PKI<sup>NES</sup> in the presence of excess RanGTP is shown in black, and triplicate competition titrations of MBP-FMRP-1b<sup>NES</sup> mutant to CRM1 and FITC-PKI<sup>NES</sup> is shown in teal. The K<sub>D</sub> values obtained are shown below the graph and numbers in brackets represent 68.3% confidence level (U=underteremined, NB=not binding).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.008">http://dx.doi.org/10.7554/eLife.23961.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp3-v2"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.009</object-id><label>Figure 1—figure supplement 4.</label><caption><title>Electron densities of the NES peptides.</title><p>2mFo-DFc map meshes contoured at 1.0σ and kicked OMIT map meshes contoured at 3.0σ are overlaid on the final coordinates of the indicated structures with NES peptides shown as sticks.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.009">http://dx.doi.org/10.7554/eLife.23961.009</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp4-v2"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.010</object-id><label>Figure 1—figure supplement 5.</label><caption><title>A longer CDC7<sup>NES</sup> peptide binds the CRM1 groove without interacting with the P4 pocket.</title><p>(<bold>A</bold>) Pull-down binding assay (~10 µg immobilized GST-CDC7<sup>NES</sup> and the longer GST-CDC7<sup>NES</sup>ext, 2.5 µM <italic><sup>Hs</sup></italic>CRM1 and 7.5 µM <italic><sup>Sc</sup></italic>RanGTP in a reaction volume of 200 µL) show that both peptides binding to CRM1. (<bold>B</bold>) Structure of the longer CDC7<sup>NES</sup>ext peptide (deep teal) bound to the CRM1 groove (grey surface). (<bold>C</bold>) 2mFo-DFc map (mesh) contoured at 0.8σ and kick OMIT map (mesh) at 2.5σ overlaid onto the final coordinates of CDC7<sup>NES</sup>ext peptide (sticks).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.010">http://dx.doi.org/10.7554/eLife.23961.010</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp5-v2"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.011</object-id><label>Figure 1—figure supplement 6.</label><caption><title>Variable number of Ф side chains are needed to have an active NES.</title><p>Sequences of wild type mDia2<sup>NES</sup>, the mDia2<sup>NES</sup>(Φ0A) and mDia2<sup>NES</sup>(AA) mutants are shown along with those for wild type PKI<sup>NES</sup> and the PKI<sup>NES</sup>(Φ4A) mutant. mDia2<sup>NES</sup>(Φ0A) and PKI<sup>NES</sup>(Φ4A) were mutated to each have only 3 Ф side chains, leucines in positions Ф1, Ф2 and Ф3. Arg1189 and Arg1191 side chains of mDia2<sup>NES</sup> make electrostatic interactions with the CRM1 groove, and were both mutated to alanines to generate the mDia2<sup>NES</sup>(AA) mutant. Affinities of MBP-mDia2<sup>NES</sup> and PKI<sup>NES</sup> mutants binding to <italic><sup>Hs</sup></italic>CRM1 were measured using differential bleaching competition assays. Fitted binding curves are overlaid onto data points plotted as mean ± SD and residuals are plotted in the bottom. K<sub>D</sub> values are reported with ranges in brackets representing the 68.3% confidence interval. *Experiments done on different days were fitted using a corresponding triplicate set of direct titrations (in black). mDia2<sup>NES</sup>(Φ0A) and PKI<sup>NES</sup>(Φ4A) bind CRM1 very differently even though they both have the same 3 Ф (Leu) side chains. mDia2<sup>NES</sup>(Φ0A) retains CRM1 binding (K<sub>D</sub> = 9.1 [7.5, 11.1] μM, vs wild type mDia2<sup>NES</sup>K<sub>D</sub> = 1.7 [1.3, 2.1] μM) but the PKI<sup>NES</sup>(Φ4A) mutant no longer binds CRM1 (K<sub>D</sub> = 150 [100, 240] μM <italic>vs</italic> wild type PKI <sup>NES</sup>K<sub>D</sub> = 35 [26, 42] nM). mDia2<sup>NES</sup>(AA) binds CRM1 2-fold tighter (K<sub>D</sub> = 800 [600, 1100] nM), suggesting that electrostatic interactions involving Arg1189 and Arg1191 of the NES are not critical for CRM1 binding. Loss of the electrostatic interactions may be compensated by the gain of helical propensity, which may lead to stabilization of the mDia2<sup>NES</sup> helix.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.011">http://dx.doi.org/10.7554/eLife.23961.011</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig1-figsupp6-v2"/></fig></fig-group></p><p>Previous structures of CRM1 bound to five different NESs showed virtually identical NES-binding grooves (<xref ref-type="bibr" rid="bib13">Fung et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Monecke et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Dong et al., 2009</xref>; <xref ref-type="bibr" rid="bib15">Güttler et al., 2010</xref>). NESs from Snurportin-1 (SNUPN<sup>NES</sup>; class 1c) and Protein Kinase A Inhibitor (PKI<sup>NES</sup>; class 1a) bind CRM1 as α-helix followed by a short β-strand, while the proline-rich NES from HIV-1 REV (Rev<sup>NES</sup>; class 2) adopts mostly extended conformation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) (<xref ref-type="bibr" rid="bib15">Güttler et al., 2010</xref>). The majority of CRM1-NES interactions involve NES hydrophobic anchor side chains, with very few polar and main chain interactions. Previously, we studied NESs with the Φ1XXΦ2XXXΦ3XXΦ4 (class 3) pattern where the <italic>i</italic>, <italic>i</italic> + 3, <italic>i</italic> + 7, <italic>i</italic> + 10 Φ positions suggested a single long amphipathic helix. However, it is perplexing that a long all-helical peptide could fit in the narrow tapering CRM1 groove. Structures of such NESs from kinase RIO2 and cytoplasmic polyadenylation element-binding protein 4 (hRio2<sup>NES</sup>, CPEB4<sup>NES</sup>) showed that they do not adopt all-helical conformations but unexpectedly adopt helix-strand conformations that bind CRM1 in the opposite or minus (−) polypeptide direction to that of SNUPN<sup>NES</sup>, PKI<sup>NES</sup> and Rev<sup>NES</sup> ((+) NESs) (<xref ref-type="bibr" rid="bib13">Fung et al., 2015</xref>). hRio2<sup>NES</sup> and CPEB4<sup>NES</sup> were hence reclassified as class 1a-R NESs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><p>We do not understand the extent of NES structural diversity nor how NESs with different hydrophobic patterns that presumably reflect different secondary structures all bind to the seemingly invariant and three-dimensionally constrained CRM1 groove. Here, eight new structures of CRM1 bound to diverse NESs show several different and unexpected NES backbone conformations that share only a common one-turn helix element. All NESs also participate in hydrogen bonding with Lys568 of <italic><sup>Hs</sup></italic>CRM1, and mutagenic/structural analysis identifies Lys568 as a selectivity filter that blocks binding of non-NES peptides.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CRM1-bound NESs adopt diverse conformations</title><p>We study three NESs that uniquely match the all-helical class 3 pattern (Ф1XXФ2XXXФ3XXФ4). Because most previously studied NESs have substantial helical content, we also study five NESs that match class 2 (Ф1XФ2XXФ3XФ4) and class 1b (Ф1XXФ2XXФ3XФ4) patterns, where the hydrophobic residue positions do not suggest an amphipathic helix (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). All eight NESs bind <italic><sup>Hs</sup></italic>CRM1 in the presence of RanGTP with dissociation constants (K<sub>D</sub>s) of 670 nM-20 μM, and were crystallized bound to the previously described engineered <italic><sup>Sc</sup></italic>CRM1-RanGppNHp-Yrb1p complex (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Figure 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="SD2-data">2</xref> and <xref ref-type="supplementary-material" rid="SD3-data">3</xref>) (<xref ref-type="bibr" rid="bib13">Fung et al., 2015</xref>). Details of how the NES peptides were modelled can be found in methods section and in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2</xref> and <xref ref-type="fig" rid="fig1s3">3</xref>. NES-bound CRM1 grooves in the structures (2.1–2.4 Å resolution) resemble the PKI<sup>NES</sup>-bound <italic><sup>Mm</sup></italic>CRM1 groove (Cα/all-atom rmsds 0.5 Å/1.1 Å for 85 groove residues), and all NESs use 4–5 hydrophobic anchor residues to bind P0-P4 hydrophobic pockets of CRM1 (<xref ref-type="fig" rid="fig1">Figures 1D–F</xref> and <xref ref-type="fig" rid="fig2">2</xref>) (<xref ref-type="bibr" rid="bib15">Güttler et al., 2010</xref>).<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.23961.012</object-id><label>Figure 2.</label><caption><title>Structures of NESs with non-helical sequence patterns.</title><p>(<bold>A–E</bold>) FMRP<sup>NES</sup> (light orange), SMAD4<sup>NES</sup> (salmon), HDAC<sup>NES</sup> (slate), Pax<sup>NES</sup> (pale cyan) and FMRP-1b<sup>NES</sup> (deep teal) bound to the <italic><sup>Sc</sup></italic>CRM1 groove. Black dashes show CRM1-NES hydrogen bonds and polar contacts, and unoccupied CRM1 hydrophobic pockets are labeled. *HDAC5<sup>NES</sup> and Pax<sup>NES</sup> sequences match the class 1b pattern, but both peptides bind CRM1 using Ф residues that match class 1a pattern. Average displacements of each Φ Cα in the eight NESs (including mDia2<sup>NES</sup>, CDC7<sup>NES</sup>, X11L2<sup>NES</sup> in <xref ref-type="fig" rid="fig1">Figure 1</xref>) from the equivalent Φ Cα of PKI<sup>NES</sup>(Ф0L) are 1.3 ± 0.6 (Φ4), 0.8 ± 0.5 (Φ3), 0.7 ± 0.4 (Φ2), 0.9 ± 0.3 (Φ1) and 1.8 ± 0.9 (Φ0) Å.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.012">http://dx.doi.org/10.7554/eLife.23961.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig2-v2"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.013</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Electron densities of the NES peptides.</title><p>2mFo-DFc map meshes contoured at 1.0σ and kicked OMIT map meshes contoured at 3.0σ are overlaid on the final coordinates of the indicated structures with NES peptides shown as sticks.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.013">http://dx.doi.org/10.7554/eLife.23961.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig2-figsupp1-v2"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.014</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Engineering class 1b NESs.</title><p>(<bold>A</bold>) Sequences of class 1b NESs generated from PKI<sup>NES</sup> and FMRP<sup>NES</sup>. The binding of mutants to CRM1 were tested in pull-down assay with ~7.5 µg immobilized GST-NESs, 2.5 µM <italic><sup>Hs</sup></italic>CRM1 and 7.5 µM<italic> <sup>Sc</sup></italic>RanGTP in 200 µL reaction volumes. The reactions were extensively washed and visualized with SDS/PAGE and Coomassie staining. (<bold>B</bold>) Leptomycin B (LMB) sensitive nuclear export activity of FMRP-1b<sup>NES</sup> was verified by expressing EYFP<sub>2</sub>-SV40<sup>NLS</sup>-FMRP-1b<sup>NES</sup> in HeLa cells and imaged with spinning disk confocal microscope (60X).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.014">http://dx.doi.org/10.7554/eLife.23961.014</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig2-figsupp2-v2"/></fig></fig-group></p><p>Class 3 NESs from mouse diaphanous homolog 3 (mDia2<sup>NES: 1179</sup>SVPE<underline>V</underline>EA<underline>L</underline>LAR<underline>L</underline>RA<underline>L</underline><sup>1193</sup>) and the cell division cycle 7-related protein kinase (CDC7<sup>NES: 456</sup>QD<underline>L</underline>RK<underline>L</underline>CER<underline>L</underline>RG<underline>M</underline>DSSTP<sup>473</sup>) are indeed all-helix peptides, both forming 3-turn α-helices that occupy only the wide part of the CRM1 groove (<xref ref-type="fig" rid="fig1">Figure 1D,E</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). The last residue of the mDia2 protein (Leu1193) binds the CRM1 P3 pocket leaving the P4 pocket empty. CDC7<sup>NES</sup> is far from the protein C-terminus but structures of longer peptides suggest that CDC7<sup>NES</sup>exits the groove after Met468 or Φ3 (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). The mDia2<sup>NES</sup> and CDC7<sup>NES</sup>sequence patterns should thus be Φ0XXΦ1XXXΦ2XXΦ3. The Φ4 anchor position is clearly not used in mDia2<sup>NES</sup> and CDC7<sup>NES</sup> even though Φ4 is key for activities of several other NESs (<xref ref-type="bibr" rid="bib46">Wen et al., 1995</xref>; <xref ref-type="bibr" rid="bib28">Meyer et al., 1996</xref>; <xref ref-type="bibr" rid="bib34">Richards et al., 1996</xref>; <xref ref-type="bibr" rid="bib37">Scott et al., 2002</xref>; <xref ref-type="bibr" rid="bib44">Tsukahara and Maru, 2004</xref>). The number of Φ anchor residues necessary for CRM1 binding can vary between 3–5 (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>). A third class 3-matching NES from beta-amyloid binding protein X11L2 (X11L2<sup>NES: 55</sup>SS<underline>L</underline>QE<underline>L</underline>VQQ<underline>F</underline>EA<underline>L</underline>PGDLV<sup>72</sup>) binds differently (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). <sup>57</sup><underline>L</underline>QE<underline>L</underline>VQQ<underline>F</underline>EA<underline>L</underline><sup>67</sup> forms a 3-turn α-helix, <sup>68</sup>PGD<underline>L</underline><sup>71</sup> forms a type I β-turn, and X11L2<sup>NES</sup> therefore exhibits a new Φ0XXΦ1XXXΦ2XXΦ3XXXΦ4 (class 4) pattern.</p><p>Structures of NESs with non-helical patterns are also informative. The previous structure of Rev<sup>NES</sup> (class 2) suggested that its three prolines may constrain against a helical conformation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) (<xref ref-type="bibr" rid="bib15">Güttler et al., 2010</xref>). Class 2 NESs in the Mothers against decapentaplegic homolog 4 protein (SMAD4<sup>NES: 133</sup>YERVVSPG<underline>I</underline>D<underline>L</underline>SG<underline>L</underline>T<underline>L</underline>Q<sup>149</sup>) and the fragile X mental retardation protein (FMRP<sup>NES: 423</sup>YLKEVDQ<underline>L</underline>R<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline><sup>437</sup>) have few to no prolines but still bind CRM1 with mostly loop-like structures (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Histone deacetylase 5 (HDAC5<sup>NES: 1082</sup>EAET<underline>V</underline>SA<underline>M</underline>AL<underline>L</underline>S<underline>V</underline>G<sup>1095</sup>) and Paxillin (Pax<sup>NES: 264</sup>RELDEL<underline>M</underline>AS<underline>L</underline>SD<underline>F</underline>K<underline>F</underline>MAQ<sup>281</sup>) have NESs with non-α-helical class 1b pattern (Ф1XXФ2XXФ3XФ4), but the peptides bind according to the class 1a pattern instead (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). This left no other experimentally verified NES in the databases that unambiguously match class 1b pattern (<xref ref-type="bibr" rid="bib22">Kosugi et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Xu et al., 2012c</xref>). We engineered a class 1b NES by adding an alanine to FMRP<sup>NES</sup> (FMRP-1b<sup>NES</sup>; YLKEVDQ<underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D), which forms a short 1.5-turn 3<sub>10</sub> helix followed by a 3-residue β-strand (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and <xref ref-type="fig" rid="fig2s2">2</xref>). The 3<sub>10</sub> helix favorably presents Φ1 and Φ2 into the CRM1 groove and natural class 1b NESs are likely to bind similarly.</p></sec><sec id="s2-2"><title>Structural requirements for an NES</title><p>Structures of &gt;13 different CRM1-bound NESs are now available, and may be sorted into five or six groups according to peptide backbone conformations (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Class 1 NESs are helix-strand peptides with either α-helices (class 1a, 1c) or 3<sub>10</sub> helices (class 1b). Class 1-R NESs are strand-helix peptides, class 2 NESs are mostly loop-like and class 3 NESs are all-helix peptides. The helix-β-turn X11L2<sup>NES</sup> structure revealed a new Φ0XXΦ1XXXΦ2XXΦ3XXXΦ4 (class 4) pattern.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.23961.015</object-id><label>Figure 3.</label><caption><title>NESs adopt diverse conformations to bind CRM1, sharing only a small one turn of the helix structural element.</title><p>(<bold>A</bold>) Overlay of 13 different CRM1-bound NESs: mDia2<sup>NES</sup>, CDC7<sup>NES</sup>, X11L2<sup>NES</sup>, FMRP<sup>NES</sup>, SMAD4<sup>NES</sup>, HDAC<sup>NES</sup>, Pax<sup>NES</sup> and FMRP-1b<sup>NES</sup>, SNUPN<sup>NES</sup> (3GB8), PKI<sup>NES</sup>(Φ0L) (3NBY), Rev<sup>NES</sup> (3NBZ), hRio2<sup>NES</sup> (5DHF), CPEB4<sup>NES</sup> (5DIF) (shown as ribbons with Φ residues in sticks; their CRM1 H12A helices were superimposed). A grey rectangle highlights the only secondary structural element shared by all 13 NESs: a single turn of helix. (<bold>B</bold>) Ramachandran plot of phi/psi angles of the four residues in each of the conserved one-turn of helix. Arrows indicate changes in psi angles along the polypeptide direction. For example, (+) HDAC5<sup>NES</sup>: Φ2 Ψ = −43.5°, Φ2<sub>+1</sub>Ψ = −21.7°, Φ2<sub>+2</sub>Ψ = −1.3°, Φ3 Ψ = 133.8° and (−) CPEB4<sup>NES</sup>: Φ2<sub>+2</sub>Ψ = −40.2°, Φ2<sub>+1</sub>Ψ = −31.0°, Φ2 Ψ = 16.5°, Φ2<sub>-1</sub>Ψ = 111.5°. *Residues in SNUPN<sup>NES</sup> plotted are Φ2<sub>+1</sub>, Φ2<sub>+2</sub>, Φ2<sub>+3</sub> and Φ3. (<bold>C</bold>) Detailed view of niche motifs in (+) NESs, FMRP<sup>NES</sup> and mDia2<sup>NES</sup>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.015">http://dx.doi.org/10.7554/eLife.23961.015</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.016</object-id><label>Figure 3—figure supplement 1.</label><caption><title>NES main chain hydrogen bonds with <italic><sup>Sc</sup></italic>CRM1 Lys579 in (−) NESs.</title><p>Structures of CPEB4<sup>NES</sup> (5DIF), hRio2<sup>NES</sup> (5DHF) and PKI<sup>NES</sup>-Flip3 mutant (5DH9) bound to <italic><sup>Sc</sup></italic>CRM1, showing hydrogen bonds made by the Lys579 side chain of <italic><sup>Sc</sup></italic>CRM1. Niche motifs observed in (+) NESs are absent here, but in CPEB4<sup>NES</sup> and PKI<sup>NES</sup>-Flip3 mutant, Lys579 is still coordinated by two main chain carbonyls from Ф1<sub>-1</sub> and Ф2<sub>-1</sub>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.016">http://dx.doi.org/10.7554/eLife.23961.016</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig3-figsupp1-v2"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.017</object-id><label>Figure 3—figure supplement 2.</label><caption><title>The Lys568 of <italic><sup>Hs</sup></italic>CRM1 is important for NES binding.</title><p>(<bold>A</bold>) Pull-down binding assays with ~5 µg immobilized GST-NESs, 500 nM wild type <italic><sup>Hs</sup></italic>CRM1, the <italic><sup>Hs</sup></italic>CRM1(K568A) or <italic><sup>Hs</sup></italic>CRM1(K568M) mutant and 1.5 µM <italic><sup>Sc</sup></italic>RanGTP in 1 mL reaction volumes. Most of the NESs showed decreased binding to the K568A and K568M mutants compared to wild type CRM1. Because of the limited dynamic range of detection in pull-down assays, it is unclear if binding of hRio2<sup>NES</sup> and X11L2<sup>NES</sup> to mutant versus wild type CRM1 proteins are different. (<bold>B</bold>) Binding affinity of FITC-PKI<sup>NES</sup> to <italic><sup>Hs</sup></italic>CRM1, <italic><sup>Hs</sup></italic>CRM1(K568A) and <italic><sup>Hs</sup></italic>CRM1(K568M) measured using differential bleaching. Different concentration regimes were used for different mutants to obtain meaningful data points and at least three titrations were performed for each CRM1. Fitted binding curves are overlaid onto data points plotted as mean ± SD and residuals are plotted in the bottom. K<sub>D</sub> values are reported with ranges in brackets representing the 68.3% confidence interval.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.017">http://dx.doi.org/10.7554/eLife.23961.017</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig3-figsupp2-v2"/></fig></fig-group></p><p>The only common secondary structural element in the NES structures is one turn of NES helix at Φ2X<sub>2-3</sub>Φ3 (grey box, <xref ref-type="fig" rid="fig3">Figure 3A</xref>). This conserved turn of helix is flanked on one side by additional turns of helix (classes 1, 1-R) or by loops (class 2), and on the other side by β-strands (classes 1, 1-R, 2) or β-turn (class 4), or the helix ends as the chain terminates or exits the groove (class 3) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Dihedral (psi) angles in the 1-turn of helix gradually increase in progression from helical to β-strand conformations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><p>In all (+) NESs, main chain carbonyls of Φ2<sub>+1</sub> and Φ3 residues in the 1-turn helix element hydrogen bonds with the <italic><sup>Sc</sup></italic>CRM1 Lys579 (or <italic><sup>Mm</sup></italic>CRM1/<italic><sup>Hs</sup></italic>CRM1 Lys568) side chain, much like niche3/4 motifs where carbonyls of residues <italic>i</italic> and <italic>i</italic> + 2 or <italic>i</italic> + 3 coordinate a cationic group (<xref ref-type="bibr" rid="bib42">Torrance et al., 2009</xref>). The Φ3-Lys579 hydrogen bond is possible only because the β-strand psi angle turns Φ3 carbonyl towards Lys579 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). NES helix-Lys579 hydrogen bonds are absent in (−) NESs as backbone carbonyls point in the opposite direction. Here, carbonyls of the N-terminal β-strand hydrogen bond with Lys579 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Therefore, another common structural feature of NESs is hydrogen bonding between NES backbone and <italic><sup>Sc</sup></italic>CRM1 Lys579 (<italic><sup>Hs</sup></italic>CRM1 Lys568). Mutations of <italic><sup>Hs</sup></italic>CRM1 Lys568 impair NES binding. Mutants <italic><sup>Hs</sup></italic>CRM1(K568A) and <italic><sup>Hs</sup></italic>CRM1(K568M) bind FITC-PKI<sup>NES</sup> two to three orders of magnitude weaker than wild type <italic><sup>Hs</sup></italic>CRM1, supporting the importance of Lys568-NES interactions (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>In summary, an active NES (1) can use many different backbone conformations to present 3–5 hydrophobic anchor residues into 3–5 CRM1 hydrophobic pockets (P0 and/or P4 are sometimes not used), (2) has one turn of helix with helix-strand transition that binds the central portion of the CRM1 groove and (3) has backbone conformation that can hydrogen bond with Lys568 of <italic><sup>Hs</sup></italic>CRM1.</p></sec><sec id="s2-3"><title><italic><sup>Hs</sup></italic>CRM1 Lys568 is a selectivity filter for NES recognition</title><p>What then are CRM1 groove features that selectively recognize the key NES features? Arrangement of hydrophobic pockets in the groove likely selects NESs with suitably placed Φ residues. Groove shape, tapering and most constricted at <italic><sup>Sc</sup></italic>CRM1 Lys579 (<italic><sup>Hs</sup></italic>CRM1 Lys568), likely selects for NES helices that transition to strands or NES helices that end (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Is groove-constricting <italic><sup>Hs</sup></italic>CRM1 Lys568 perhaps key for differentiating active from false positive NES sequences? We tested mutants <italic><sup>Hs</sup></italic>CRM1(K568A) and <italic><sup>Hs</sup></italic>CRM1(K568M) for interactions with three previously identified false positive NESs that match NES consensus but do not bind CRM1: peptides from Hexokinase-2 (Hxk2<sup>pep: 18</sup>DVPKE<underline>L</underline>MQQ<underline>I</underline>EN<underline>F</underline>EK<underline>I</underline>FTV<sup>36</sup>, class 3 match), Deformed Epidermal Autoregulatory Factor 1 homolog (DEAF1<sup>pep:452</sup>SW<underline>L</underline>Y<underline>L</underline>EE<underline>M</underline>VNS<underline>L</underline>LNTAQQ<sup>469</sup>; class 1a-R match) and COMM domain-containing protein 1 (COMMD1<sup>pep; 173</sup>KT<underline>L</underline>SE<underline>V</underline>EES<underline>I</underline>ST<underline>L</underline>ISQPN<sup>190</sup>; class 3 match) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) (<xref ref-type="bibr" rid="bib48">Xu et al., 2012c</xref>, <xref ref-type="bibr" rid="bib50">2015</xref>). Wild type <italic><sup>Hs</sup></italic>CRM1 does not bind the peptides but <italic><sup>Hs</sup></italic>CRM1(K568A) binds Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup>, and <italic><sup>Hs</sup></italic>CRM1(K568M) binds DEAF1<sup>pep</sup> but not Hxk2<sup>pep</sup>, suggesting that Lys568 is important in filtering out false positive NESs (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.23961.018</object-id><label>Figure 4.</label><caption><title><italic><sup>Hs</sup></italic>CRM1 Lys568 is a selectivity filter.</title><p>(<bold>A</bold>) False positive NES sequences with Φ residues of consensus matches underlined. Pull-down binding assay of ~5 µg immobilized GST-NESs and 7.5 µM <italic><sup>Sc</sup></italic>RanGTP with 2.5 µM of either wild type <italic><sup>Hs</sup></italic>CRM1 or mutant <italic><sup>Hs</sup></italic>CRM1(K568A) or <italic><sup>Hs</sup></italic>CRM1(K568M) in 200 µL reactions. (<bold>C–D</bold>) Structures of Hxk2<sup>pep</sup> (pink) (<bold>C</bold>) and DEAF1<sup>pep</sup> (purple) (<bold>D</bold>) bound to <italic><sup>Sc</sup></italic>CRM1(K579A). Left panels, peptides were removed to show the surface of the mutant <italic><sup>Sc</sup></italic>CRM1(K579A) groove. Middle panels, peptides bound to the mutant <italic><sup>Sc</sup></italic>CRM1(K579A). Right panels, CRM1(K579A)-bound Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> superimposed onto the PKI<sup>NES</sup>(Ф0L)-bound <italic><sup>Mm</sup></italic>CRM1 groove (3NBY; CRM1 H12A helices were aligned; PKI<sup>NES</sup> not shown) to show steric clash of the Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> peptides with the <italic><sup>Mm</sup></italic>CRM1 Lys568 side chain.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.018">http://dx.doi.org/10.7554/eLife.23961.018</ext-link></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.23961.019</object-id><label>Figure 4—source data 1.</label><caption><title>Data collection and refinement statistics and crystallization conditions.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.019">http://dx.doi.org/10.7554/eLife.23961.019</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-23961-fig4-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig4-v2"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.020</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Electron densities of the HXK2<sup>pep</sup> and DEAF<sup>pep</sup> false positive NES peptides bound to the <italic><sup>Sc</sup></italic>CRM1(K579A) mutant.</title><p>2mFo-DFc map meshes contoured at 0.8σ and kicked OMIT map meshes contoured at 3.0σ are overlaid on the final coordinates of the indicated structures with NES peptides shown as sticks.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.020">http://dx.doi.org/10.7554/eLife.23961.020</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig4-figsupp1-v2"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.23961.021</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Additional overlays of Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> onto NES-bound wild type CRM1 grooves.</title><p>(<bold>A</bold>) Hxk2<sup>pep</sup>-<italic><sup>Sc</sup></italic>CRM1(K579A) (Hxk2<sup>pep</sup> in pink cartoon and <italic><sup>Sc</sup></italic>CRM1(K579A) shown as grey surface) superimposed onto the PKI<sup>NES</sup>(Ф0L)-bound <italic><sup>Mm</sup></italic>CRM1 groove (wild type CRM1, 3NBY; blue surface), the Pax<sup>NES</sup>- bound <italic><sup>Sc</sup></italic>CRM1 groove (pale cyan), the FMRP<sup>NES</sup>-bound <italic><sup>Sc</sup></italic>CRM1 (wheat) and the mDia2<sup>NES</sup>-bound <italic><sup>Sc</sup></italic>CRM1 (pale green) by aligning their CRM1 H12A helices. The superpositions show steric clash of the Hxk2<sup>pep</sup> peptide with the <italic><sup>Mm</sup></italic>CRM1 Lys568 or <italic><sup>Sc</sup></italic>CRM1 Lys579 side chains. (<bold>B</bold>) DEAF1<sup>pep</sup>-<italic><sup>Sc</sup></italic>CRM1(K579A) (DEAF<sup>pep</sup> in magenta cartoon and <italic><sup>Sc</sup></italic>CRM1(K579A) shown as grey surface) superimposed onto the PKI<sup>NES</sup>(Ф0L)-bound <italic><sup>Mm</sup></italic>CRM1 groove (wild type CRM1, 3NBY; blue surface), the hRio2<sup>NES</sup>-bound <italic><sup>Sc</sup></italic>CRM1 (orange, 5DHF) and the CPEB4<sup>NES</sup>-bound <italic><sup>Sc</sup></italic>CRM1 (yellow, 5DIF). The N-terminus of DEAF1<sup>pep</sup> clashes with of <italic><sup>Mm</sup></italic>CRM1 Lys568 or<italic> <sup>Sc</sup></italic>CRM1 Lys579 side chains. Zoomed in views are rotated to show proximity of DEAF1<sup>pep</sup> Ф1XФ2 to the <italic><sup>Sc</sup></italic>CRM1 Lys579 side chain.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23961.021">http://dx.doi.org/10.7554/eLife.23961.021</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-23961-fig4-figsupp2-v2"/></fig></fig-group></p><p>Both <italic><sup>Sc</sup></italic>CRM1(K579A)-bound Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> are all-helix peptides (<xref ref-type="fig" rid="fig4">Figure 4B,C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 4—source data 1</xref>). The fourth turn of the Hxk2<sup>pep</sup> helix packs into hydrophobic space widened by removal and rearrangement of the Lys579 and Glu582 side chains, respectively (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The 2.5-turn α-helix of DEAF1<sup>pep</sup>binds in the (−) direction and is slightly longer than helices in true (−) NESs (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Superpositions of Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> onto wild type CRM1 grooves show the fourth turn of the Hxk2<sup>pep</sup> helix and the N-terminus of the DEAF1<sup>pep</sup> helix clashing with <italic><sup>Sc</sup></italic>CRM1 Lys579/<italic><sup>Mm</sup></italic>CRM1 Lys568 side chains (<xref ref-type="fig" rid="fig4">Figure 4B,C</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). The rest of the mutant <italic><sup>Sc</sup></italic>CRM1(K579A) groove is highly similar to the wild type groove. Therefore, the key feature of the wild type groove that prevents Hxk2<sup>pep</sup> and DEAF1<sup>pep</sup> binding is Lys568, which is not only a critical hydrogen bond donor for binding NESs, but its long side chain also blocks binding of sequences that do not meet NES structural requirements.</p></sec></sec><sec id="s3"><title>Discussions</title><p>Class 1a, 1b, 1c, 2, 3, 4 and 1a-R NES structures show 5–6 distinct backbone conformations that match their respective hydrophobic sequence patterns. We can infer structures of remaining NES classes: class 1d NESs (Ф1XXФ2XXXФ3XФ4) are likely α-helix-strand and other (−) NES classes are likely the reverse of their (+) counterparts. Symmetrical class 2, 3 and 4 patterns are identical in both (+)/(−) directions but (−) class 3 and 4 NESs, lacking β-strands to hydrogen bond with <italic><sup>Hs</sup></italic>CRM1 Lys568, may not be ideal NESs.</p><p>Structures of many diverse NES sequences suggest how one unchanging peptide-bound CRM1 groove can recognize up to a thousand different peptides. Dependence of 3–5 hydrophobic residues in 8–15 residues-long NES arises from the substantial binding energy of anchor hydrophobic side chains interacting with 3–5 CRM1 hydrophobic pockets. However, lack of contact with NES backbone allows anchor side chains to be presented in many conformations including both N- to C-terminal orientations, explaining broad specificity defined by highly variable spacings between anchors. Interestingly, NES conformation is not entirely unrestrained, as CRM1 groove constriction imposes either exit/termination of the NES chain or its continuation in extended configuration. Solutions for the broadly specific NES recognition contrast with those of analogous systems. MHC I and II proteins, each recognizing at least hundreds of different peptide antigens, use many peptide main chain contacts for affinity with only a few supplementary peptide side chain interactions (<xref ref-type="bibr" rid="bib52">Zhang et al., 1998</xref>; <xref ref-type="bibr" rid="bib26">Madden, 1995</xref>). The result here is a conformational selection of particular lengths of extended peptides binding in conserved N- to C-terminal orientation, with little sequence restriction. The Calmodulin-helical peptide system is yet another contrast, as the binding domain uses its flexible fold to adapt to various helical ligands (<xref ref-type="bibr" rid="bib41">Tidow and Nissen, 2013</xref>; <xref ref-type="bibr" rid="bib17">Hoeflich and Ikura, 2002</xref>).</p><p>CRM1-NES structures expanded the six NES patterns derived from peptide library studies to the eleven patterns shown in <xref ref-type="fig" rid="fig1">Figures 1A</xref> and <xref ref-type="fig" rid="fig3">3A</xref>. The ever-expanding set of NES patterns suggests that no fixed hydrophobic pattern likely describes the NES. Furthermore, only ~50% of consensus-matching previously reported NESs that were tested actually bound CRM1, contributing to the inefficiency of available NES predictors (with precision of 50% at 20% recall rate) (<xref ref-type="bibr" rid="bib47">Xu et al., 2012b</xref>, <xref ref-type="bibr" rid="bib50">2015</xref>; <xref ref-type="bibr" rid="bib23">Kosugi et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Fu et al., 2011</xref>). The many available NES structures, diversity of NES conformations and the structurally conserved one-turn helix NES element revealed here will enable development of structure- rather than sequence-based NES predictors (<xref ref-type="bibr" rid="bib33">Raveh et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Schindler et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Trellet et al., 2013</xref>; <xref ref-type="bibr" rid="bib51">Yan et al., 2016</xref>). There is a need to identify many more CRM1 cargoes as apoptosis of different cancer cells upon CRM1 inhibition by the drug Selinexor (in clinical trials for a variety of cancers) and other inhibitors (<xref ref-type="bibr" rid="bib31">Parikh et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Mendonca et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Das et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Alexander et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Gounder et al., 2016</xref>; <xref ref-type="bibr" rid="bib1">Abdul Razak et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Lapalombella et al., 2012</xref>; <xref ref-type="bibr" rid="bib18">Inoue et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Etchin et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Tai et al., 2014</xref>; <xref ref-type="bibr" rid="bib6">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Hing et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Vercruysse et al., 2016</xref>) appears to be driven by nuclear accumulation of different sets of NES-containing cargoes, but identities of most of these apoptosis-causing cargoes are still unknown.</p><p>Finally, we find that the <italic><sup>Hs</sup></italic>CRM1 Lys568 side chain acts as a filter that physically selects for NESs with helices that transition to strands or end at the narrow part of the CRM1 groove. Interestingly, Lys568 interacts electrostatically with <italic><sup>Hs</sup></italic>CRM1 Glu571, which is mutated to glycine or lysine in chronic lymphocytic leukemia and lymphomas with poor prognosis (<xref ref-type="bibr" rid="bib32">Puente et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Jardin et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Camus et al., 2016</xref>). Disease mutations will abolish Glu571-Lys568 contacts and possibly affect NES binding and selectivity.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Crystallization of CRM1-Ran-RanBP1-NES complexes</title><p>CRM1 (<italic><sup>Sc</sup></italic>CRM1 residues 1–1058, △377–413, <sup>537</sup>DLTVK<sup>541</sup> to GLCEQ, V441D), Yrb1p (yeast RanBP1 residues 62–201), human Ran full length and various NESs were expressed and purified as described in Fung et al. (<xref ref-type="bibr" rid="bib13">Fung et al., 2015</xref>). CRM1 (K579A) mutant was expressed in pGex-TEV and purified like CRM1. Crystallization, data collection and processing, and solving of the structures were also performed in the same manner as previously described. X-ray/stereochemistry weight and X-ray/ADP weight were both optimized by phenix.refine in PHENIX (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014224">SCR_014224</ext-link>).</p><p>NES peptides are modeled according to the positive difference density (2mFo-DFc map) at the binding groove after refinement of the CRM1-Ran-RanBP1 model. In all structures, there are good electron densities for the NES main chain and directions of side chain density in the helical portion of the peptides allow unambiguous determination that they are all oriented in the positive (+) NES orientation. Side chain assignments of the NES peptides are guided by (1) densities of Ф side chains that point into the binding groove, (2) densities for long non-Ф side chains such as arginine, phenylalanine and methionine and (3) physical considerations such as steric clashes.</p><p>For example, to model the bound mDia2<sup>NES</sup> peptide (sequence: GGSY-<sup>1179</sup>SVPEVEALLARLRAL<sup>1193</sup>), we made use of the obvious electron densities (mFo-DFc map) for long side chains to guide sequence assignment. There is a strong side chain density suitable for an arginine side chain on the peptide (white dashed circle in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). There are only two arginine residues in the mDia2<sup>NES</sup> peptide, Arg1189 and Arg1191. If the long side chain density is assigned to Arg1189, then Arg1191 would end up pointing into the binding groove – a very energetically unfavorable and unlikely situation. Furthermore, Ala1188 would end up in the P2 pocket of CRM1 where there is an obvious density for a longer hydrophobic side chain (left panel, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). On the other hand, when Arg1191 is assigned to the long and continuous side chain density (adjacent to helix H12A of CRM1), the remaining side chains in the NES end up in positions that are consistent the electron densities.</p><p>For the FMRP-1b<sup>NES</sup> (sequence: <sup>1</sup>GGS-YLKEVDQLRALERLQID<sup>20</sup>), there are no obvious long side chain densities that could help with modeling. There are however obvious densities for several side chains in the first two turn of the NES helix. These side chain densities are consistent with two possible sequence assignments: <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup> or the more C-terminal <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup>. We tested modeling of FMRP-1b<sup>NES</sup> by refining both peptide models and by testing a mutant peptide that should distinguish between the two models. Ten cycles of PHENIX refinement of the <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup> model resulted in positive and negative difference densities (mFo-DFc map) at several NES side chains, which suggested an incorrect assignment (left panels, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). In contrast, different densities are absent when the <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> model is refined (right panels, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). The final FMRP-1b<sup>NES</sup> structure was therefore modelled as <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup>. The sequence assignment of FMRP-1b<sup>NES</sup> was also tested using a mutant FMRP-1b<sup>NES</sup> that has the sequence YLKEVDQLRALER. If the NES is <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup>, FMRP-1b<sup>NES</sup> mutant YLKEVDQLRALER should bind well to CRM1. However, if <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> is the FMRP-1b<sup>NES</sup>, mutant YLKEVDQLRALER should not bind CRM1 as the C-terminal half of the NES or <sup>17</sup><underline>L</underline>Q<underline>I</underline>D<sup>20</sup> which includes Ф3 and Ф4 is missing. Results in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> show that FMRP-1b<sup>NES</sup> mutant YLKEVDQLRALER does not bind CRM1, providing further support that the NES is indeed <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> as currently assigned.</p></sec><sec id="s4-2"><title>NES activity assays</title><p>Pull-down binding assays, in vivo NES activity assay and differential bleaching experiments for determining binding affinities were all performed the same way as described in <xref ref-type="bibr" rid="bib13">Fung et al. (2015)</xref>. The data were analyzed in PALMIST (<xref ref-type="bibr" rid="bib35">Scheuermann et al., 2016</xref>) and plotted with GUSSI (<xref ref-type="bibr" rid="bib4">Brautigam, 2015</xref>).</p></sec><sec id="s4-3"><title>Accession codes</title><p>Structures and crystallographic data have been deposited at the PDB: 5UWI (CRM1-HDAC5<sup>NES</sup>), 5UWH (CRM1-Pax<sup>NES</sup>), 5UWO (CRM1-FMRP-1b<sup>NES</sup>), 5UWJ (CRM1-FMRP<sup>NES</sup>), 5UWU (CRM1-SMAD4<sup>NES</sup>) 5UWP (CRM1-mDia2<sup>NES</sup>), 5UWQ (CRM1-CDC7<sup>NES</sup>), 5UWR (CRM1-CDC7<sup>NES</sup> ext), 5UWS (CRM1-X11L2<sup>NES</sup>), 5UWT (CRM1(K579A)-Hxk2<sup>pep</sup>), 5UWW (CRM1(K579A)-DEAF1<sup>pep</sup>).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the Structural Biology Laboratory and Macromolecular Biophysics Resource at UTSW for their assistance with crystallographic and biophysical data collection. Results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. Argonne is operated by UChicago Argonne, LLC, for the US Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. Ho Yee Joyce Fung is a Howard Hughes Medical Institute International Student Research fellow. This work was funded by the Cancer Prevention Research Institute of Texas (CPRIT) Grants RP120352 and RP150053 (YMC), R01 GM069909 (YMC), the Welch Foundation Grant I-1532 (YMC), Leukemia and Lymphoma Society Scholar Award (YMC), the University of Texas Southwestern Endowed Scholars Program (YMC), and a Croucher Foundation Scholarship (HYJF).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>HYJF, Conceptualization, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>S-CF, Formal analysis, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>YMC, Conceptualization, Supervision, Funding acquisition, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWI" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of HDAC5 NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWI">http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWI</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWI)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro2" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWH" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of Paxillin NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWH">www.rcsb.org/pdb/explore/explore.do?structureId=5UWH</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWH)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro3" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWO" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of Engineered FMRP-1b NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWO">www.rcsb.org/pdb/explore/explore.do?structureId=5UWO</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWO)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro4" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWJ" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of FMRP NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWJ">www.rcsb.org/pdb/explore/explore.do?structureId=5UWJ</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWJ)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro5" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWU" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of SMAD4 NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWU">www.rcsb.org/pdb/explore/explore.do?structureId=5UWU</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWU)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro6" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWP" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of mDia2 NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWP">www.rcsb.org/pdb/explore/explore.do?structureId=5UWP</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWP)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro7" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWQ" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of CDC7 NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWQ">www.rcsb.org/pdb/explore/explore.do?structureId=5UWQ</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWQ)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro8" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWR" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of CDC7 NES Peptide (extended) in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWR">www.rcsb.org/pdb/explore/explore.do?structureId=5UWR</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWR)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro9" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWS" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of X11L2 NES Peptide in complex with CRM1-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWS">www.rcsb.org/pdb/explore/explore.do?structureId=5UWS</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWS)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro10" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWT" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of Hxk2 Peptide in complex with CRM1 K579A mutant-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWT">www.rcsb.org/pdb/explore/explore.do?structureId=5UWT</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWT)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro11" source-id="www.rcsb.org/pdb/explore/explore.do?structureId=5UWW" source-id-type="uri"><collab>Ho Yee Joyce Fung</collab><x>,</x> <collab>Yuh Min Chook</collab><x>,</x> <year>2017</year><x>,</x><source>Crystal Structure of DEAF1 Peptide in complex with CRM1 K579A mutant-Ran-RanBP1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/explore/explore.do?structureId=5UWW">www.rcsb.org/pdb/explore/explore.do?structureId=5UWW</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5UWW)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul Razak</surname><given-names>AR</given-names></name><name><surname>Mau-Soerensen</surname><given-names>M</given-names></name><name><surname>Gabrail</surname><given-names>NY</given-names></name><name><surname>Gerecitano</surname><given-names>JF</given-names></name><name><surname>Shields</surname><given-names>AF</given-names></name><name><surname>Unger</surname><given-names>TJ</given-names></name><name><surname>Saint-Martin</surname><given-names>JR</given-names></name><name><surname>Carlson</surname><given-names>R</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>McCauley</surname><given-names>D</given-names></name><name><surname>Rashal</surname><given-names>T</given-names></name><name><surname>Lassen</surname><given-names>U</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Stayner</surname><given-names>LA</given-names></name><name><surname>Mirza</surname><given-names>MR</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Mahipal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>First-in-class, first-in-human phase I study of Selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>4142</fpage><lpage>4150</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.65.3949</pub-id><pub-id pub-id-type="pmid">26926685</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>TB</given-names></name><name><surname>Lacayo</surname><given-names>NJ</given-names></name><name><surname>Choi</surname><given-names>JK</given-names></name><name><surname>Ribeiro</surname><given-names>RC</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Rubnitz</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>4094</fpage><lpage>4101</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.67.5066</pub-id><pub-id pub-id-type="pmid">27507877</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogerd</surname><given-names>HP</given-names></name><name><surname>Fridell</surname><given-names>RA</given-names></name><name><surname>Benson</surname><given-names>RE</given-names></name><name><surname>Hua</surname><given-names>J</given-names></name><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Protein sequence requirements for function of the human T-cell leukemia virus type 1 rex nuclear export signal delineated by a novel in vivo randomization-selection assay</article-title><source>Molecular and Cellular Biology</source><volume>16</volume><fpage>4207</fpage><lpage>4214</lpage><pub-id pub-id-type="doi">10.1128/MCB.16.8.4207</pub-id><pub-id pub-id-type="pmid">8754820</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brautigam</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Calculations and Publication-Quality illustrations for analytical ultracentrifugation data</article-title><source>Methods in Enzymology</source><volume>562</volume><fpage>109</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2015.05.001</pub-id><pub-id pub-id-type="pmid">26412649</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camus</surname><given-names>V</given-names></name><name><surname>Stamatoullas</surname><given-names>A</given-names></name><name><surname>Mareschal</surname><given-names>S</given-names></name><name><surname>Viailly</surname><given-names>PJ</given-names></name><name><surname>Sarafan-Vasseur</surname><given-names>N</given-names></name><name><surname>Bohers</surname><given-names>E</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Picquenot</surname><given-names>JM</given-names></name><name><surname>Ruminy</surname><given-names>P</given-names></name><name><surname>Maingonnat</surname><given-names>C</given-names></name><name><surname>Bertrand</surname><given-names>P</given-names></name><name><surname>Cornic</surname><given-names>M</given-names></name><name><surname>Tallon-Simon</surname><given-names>V</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Veresezan</surname><given-names>L</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><name><surname>Vera</surname><given-names>P</given-names></name><name><surname>Bastard</surname><given-names>C</given-names></name><name><surname>Tilly</surname><given-names>H</given-names></name><name><surname>Jardin</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical hodgkin lymphoma</article-title><source>Haematologica</source><volume>101</volume><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.3324/haematol.2016.145102</pub-id><pub-id pub-id-type="pmid">27479820</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Holloway</surname><given-names>MP</given-names></name><name><surname>Nguyen</surname><given-names>K</given-names></name><name><surname>McCauley</surname><given-names>D</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Kauffman</surname><given-names>MG</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Altura</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast Cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>13</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0416</pub-id><pub-id pub-id-type="pmid">24431073</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Parikh</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Selective inhibitors of nuclear export (SINE) in hematological malignancies</article-title><source>Experimental Hematology &amp; Oncology</source><volume>4</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s40164-015-0002-5</pub-id><pub-id pub-id-type="pmid">25745591</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Süel</surname><given-names>KE</given-names></name><name><surname>Jackson</surname><given-names>LK</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structural basis for leucine-rich nuclear export signal recognition by CRM1</article-title><source>Nature</source><volume>458</volume><fpage>1136</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1038/nature07975</pub-id><pub-id pub-id-type="pmid">19339969</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etchin</surname><given-names>J</given-names></name><name><surname>Sanda</surname><given-names>T</given-names></name><name><surname>Mansour</surname><given-names>MR</given-names></name><name><surname>Kentsis</surname><given-names>A</given-names></name><name><surname>Montero</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>BT</given-names></name><name><surname>Christie</surname><given-names>AL</given-names></name><name><surname>McCauley</surname><given-names>D</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Stone</surname><given-names>R</given-names></name><name><surname>Letai</surname><given-names>A</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Thomas Look</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia</article-title><source>British Journal of Haematology</source><volume>161</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/bjh.12231</pub-id><pub-id pub-id-type="pmid">23373539</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornerod</surname><given-names>M</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Mattaj</surname><given-names>IW</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>CRM1 is an export receptor for leucine-rich nuclear export signals</article-title><source>Cell</source><volume>90</volume><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80371-2</pub-id><pub-id pub-id-type="pmid">9323133</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>SC</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Horton</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prediction of leucine-rich nuclear export signal containing proteins with NESsential</article-title><source>Nucleic Acids Research</source><volume>39</volume><elocation-id>e111</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkr493</pub-id><pub-id pub-id-type="pmid">21705415</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Yanagida</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>CRM1 is responsible for intracellular transport mediated by the nuclear export signal</article-title><source>Nature</source><volume>390</volume><fpage>308</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1038/36894</pub-id><pub-id pub-id-type="pmid">9384386</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>HY</given-names></name><name><surname>Fu</surname><given-names>SC</given-names></name><name><surname>Brautigam</surname><given-names>CA</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural determinants of nuclear export signal orientation in binding to exportin CRM1</article-title><source>eLife</source><volume>4</volume><elocation-id>10034</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10034</pub-id><pub-id pub-id-type="pmid">26349033</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gounder</surname><given-names>MM</given-names></name><name><surname>Zer</surname><given-names>A</given-names></name><name><surname>Tap</surname><given-names>WD</given-names></name><name><surname>Salah</surname><given-names>S</given-names></name><name><surname>Dickson</surname><given-names>MA</given-names></name><name><surname>Gupta</surname><given-names>AA</given-names></name><name><surname>Keohan</surname><given-names>ML</given-names></name><name><surname>Loong</surname><given-names>HH</given-names></name><name><surname>D'Angelo</surname><given-names>SP</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Condy</surname><given-names>M</given-names></name><name><surname>Nyquist-Schultz</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>L</given-names></name><name><surname>Erinjeri</surname><given-names>JP</given-names></name><name><surname>Jasmine</surname><given-names>FH</given-names></name><name><surname>Friedlander</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>R</given-names></name><name><surname>Unger</surname><given-names>TJ</given-names></name><name><surname>Saint-Martin</surname><given-names>JR</given-names></name><name><surname>Rashal</surname><given-names>T</given-names></name><name><surname>Ellis</surname><given-names>J</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Abdul Razak</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phase IB study of selinexor, a First-in-Class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>3166</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.67.6346</pub-id><pub-id pub-id-type="pmid">27458288</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Güttler</surname><given-names>T</given-names></name><name><surname>Madl</surname><given-names>T</given-names></name><name><surname>Neumann</surname><given-names>P</given-names></name><name><surname>Deichsel</surname><given-names>D</given-names></name><name><surname>Corsini</surname><given-names>L</given-names></name><name><surname>Monecke</surname><given-names>T</given-names></name><name><surname>Ficner</surname><given-names>R</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1931</pub-id><pub-id pub-id-type="pmid">20972448</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hing</surname><given-names>ZA</given-names></name><name><surname>Fung</surname><given-names>HY</given-names></name><name><surname>Ranganathan</surname><given-names>P</given-names></name><name><surname>Mitchell</surname><given-names>S</given-names></name><name><surname>El-Gamal</surname><given-names>D</given-names></name><name><surname>Woyach</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Goettl</surname><given-names>VM</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Cagatay</surname><given-names>T</given-names></name><name><surname>Lehman</surname><given-names>AM</given-names></name><name><surname>Lucas</surname><given-names>DM</given-names></name><name><surname>Baloglu</surname><given-names>E</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Kauffman</surname><given-names>MG</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Lapalombella</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies</article-title><source>Leukemia</source><volume>30</volume><fpage>2364</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1038/leu.2016.136</pub-id><pub-id pub-id-type="pmid">27323910</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Ikura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Calmodulin in action: diversity in target recognition and activation mechanisms</article-title><source>Cell</source><volume>108</volume><fpage>739</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00682-7</pub-id><pub-id pub-id-type="pmid">11955428</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>CP</given-names></name><name><surname>Weiss</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CRM1 blockade by selective inhibitors of nuclear export attenuates kidney Cancer growth</article-title><source>The Journal of Urology</source><volume>189</volume><fpage>2317</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.10.018</pub-id><pub-id pub-id-type="pmid">23079374</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardin</surname><given-names>F</given-names></name><name><surname>Pujals</surname><given-names>A</given-names></name><name><surname>Pelletier</surname><given-names>L</given-names></name><name><surname>Bohers</surname><given-names>E</given-names></name><name><surname>Camus</surname><given-names>V</given-names></name><name><surname>Mareschal</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Sola</surname><given-names>B</given-names></name><name><surname>Ochmann</surname><given-names>M</given-names></name><name><surname>Lemonnier</surname><given-names>F</given-names></name><name><surname>Viailly</surname><given-names>PJ</given-names></name><name><surname>Bertrand</surname><given-names>P</given-names></name><name><surname>Maingonnat</surname><given-names>C</given-names></name><name><surname>Traverse-Glehen</surname><given-names>A</given-names></name><name><surname>Gaulard</surname><given-names>P</given-names></name><name><surname>Damotte</surname><given-names>D</given-names></name><name><surname>Delarue</surname><given-names>R</given-names></name><name><surname>Haioun</surname><given-names>C</given-names></name><name><surname>Argueta</surname><given-names>C</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Salles</surname><given-names>G</given-names></name><name><surname>Jais</surname><given-names>JP</given-names></name><name><surname>Figeac</surname><given-names>M</given-names></name><name><surname>Copie-Bergman</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>TJ</given-names></name><name><surname>Picquenot</surname><given-names>JM</given-names></name><name><surname>Cornic</surname><given-names>M</given-names></name><name><surname>Fest</surname><given-names>T</given-names></name><name><surname>Milpied</surname><given-names>N</given-names></name><name><surname>Lemasle</surname><given-names>E</given-names></name><name><surname>Stamatoullas</surname><given-names>A</given-names></name><name><surname>Moeller</surname><given-names>P</given-names></name><name><surname>Dyer</surname><given-names>MJ</given-names></name><name><surname>Sundstrom</surname><given-names>C</given-names></name><name><surname>Bastard</surname><given-names>C</given-names></name><name><surname>Tilly</surname><given-names>H</given-names></name><name><surname>Leroy</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma</article-title><source>American Journal of Hematology</source><volume>91</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1002/ajh.24451</pub-id><pub-id pub-id-type="pmid">27312795</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kırlı</surname><given-names>K</given-names></name><name><surname>Karaca</surname><given-names>S</given-names></name><name><surname>Dehne</surname><given-names>HJ</given-names></name><name><surname>Samwer</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>KT</given-names></name><name><surname>Lenz</surname><given-names>C</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning</article-title><source>eLife</source><volume>4</volume><elocation-id>11466</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11466</pub-id><pub-id pub-id-type="pmid">26673895</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>McMillan</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Venkateswaran</surname><given-names>N</given-names></name><name><surname>Makkar</surname><given-names>G</given-names></name><name><surname>Rodriguez-Canales</surname><given-names>J</given-names></name><name><surname>Villalobos</surname><given-names>P</given-names></name><name><surname>Neggers</surname><given-names>JE</given-names></name><name><surname>Mendiratta</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Senapedis</surname><given-names>W</given-names></name><name><surname>Baloglu</surname><given-names>E</given-names></name><name><surname>Chow</surname><given-names>CB</given-names></name><name><surname>Frink</surname><given-names>RE</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Daelemans</surname><given-names>D</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Posner</surname><given-names>BA</given-names></name><name><surname>Scaglioni</surname><given-names>PP</given-names></name><name><surname>White</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung Cancer</article-title><source>Nature</source><volume>538</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature19771</pub-id><pub-id pub-id-type="pmid">27680702</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosugi</surname><given-names>S</given-names></name><name><surname>Hasebe</surname><given-names>M</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Yanagawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nuclear export signal consensus sequences defined using a localization-based yeast selection system</article-title><source>Traffic</source><volume>9</volume><fpage>2053</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00825.x</pub-id><pub-id pub-id-type="pmid">18817528</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosugi</surname><given-names>S</given-names></name><name><surname>Yanagawa</surname><given-names>H</given-names></name><name><surname>Terauchi</surname><given-names>R</given-names></name><name><surname>Tabata</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NESmapper: accurate prediction of leucine-rich nuclear export signals using activity-based profiles</article-title><source>PLoS Computational Biology</source><volume>10</volume><elocation-id>e1003841</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003841</pub-id><pub-id pub-id-type="pmid">25233087</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>la Cour</surname><given-names>T</given-names></name><name><surname>Kiemer</surname><given-names>L</given-names></name><name><surname>Mølgaard</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Skriver</surname><given-names>K</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Analysis and prediction of leucine-rich nuclear export signals</article-title><source>Protein Engineering Design and Selection</source><volume>17</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1093/protein/gzh062</pub-id><pub-id pub-id-type="pmid">15314210</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapalombella</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Tangeman</surname><given-names>L</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Goettl</surname><given-names>V</given-names></name><name><surname>Mahoney</surname><given-names>E</given-names></name><name><surname>Berglund</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><name><surname>Mani</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>AJ</given-names></name><name><surname>Lucas</surname><given-names>D</given-names></name><name><surname>Mo</surname><given-names>X</given-names></name><name><surname>Daelemans</surname><given-names>D</given-names></name><name><surname>Sandanayaka</surname><given-names>V</given-names></name><name><surname>Shechter</surname><given-names>S</given-names></name><name><surname>McCauley</surname><given-names>D</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia</article-title><source>Blood</source><volume>120</volume><fpage>4621</fpage><lpage>4634</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-05-429506</pub-id><pub-id pub-id-type="pmid">23034282</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madden</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>The three-dimensional structure of peptide-MHC complexes</article-title><source>Annual Review of Immunology</source><volume>13</volume><fpage>587</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.13.040195.003103</pub-id><pub-id pub-id-type="pmid">7612235</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendonca</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Hammers</surname><given-names>H</given-names></name><name><surname>Meeker</surname><given-names>A</given-names></name><name><surname>De Marzo</surname><given-names>A</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Kachhap</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate Cancer</article-title><source>Oncotarget</source><volume>5</volume><fpage>6102</fpage><lpage>6112</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2174</pub-id><pub-id pub-id-type="pmid">25026284</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>BE</given-names></name><name><surname>Meinkoth</surname><given-names>JL</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious Anemia virus rev proteins: identification of a family of transferable nuclear export signals</article-title><source>Journal of Virology</source><volume>70</volume><fpage>2350</fpage><lpage>2359</lpage><pub-id pub-id-type="pmid">8642662</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monecke</surname><given-names>T</given-names></name><name><surname>Güttler</surname><given-names>T</given-names></name><name><surname>Neumann</surname><given-names>P</given-names></name><name><surname>Dickmanns</surname><given-names>A</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name><name><surname>Ficner</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP</article-title><source>Science</source><volume>324</volume><fpage>1087</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1126/science.1173388</pub-id><pub-id pub-id-type="pmid">19389996</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ossareh-Nazari</surname><given-names>B</given-names></name><name><surname>Bachelerie</surname><given-names>F</given-names></name><name><surname>Dargemont</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Evidence for a role of CRM1 in signal-mediated nuclear protein export</article-title><source>Science</source><volume>278</volume><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1126/science.278.5335.141</pub-id><pub-id pub-id-type="pmid">9311922</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>K</given-names></name><name><surname>Cang</surname><given-names>S</given-names></name><name><surname>Sekhri</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents</article-title><source>Journal of Hematology &amp; Oncology</source><volume>7</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-014-0078-0</pub-id><pub-id pub-id-type="pmid">25316614</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Pinyol</surname><given-names>M</given-names></name><name><surname>Quesada</surname><given-names>V</given-names></name><name><surname>Conde</surname><given-names>L</given-names></name><name><surname>Ordóñez</surname><given-names>GR</given-names></name><name><surname>Villamor</surname><given-names>N</given-names></name><name><surname>Escaramis</surname><given-names>G</given-names></name><name><surname>Jares</surname><given-names>P</given-names></name><name><surname>Beà</surname><given-names>S</given-names></name><name><surname>González-Díaz</surname><given-names>M</given-names></name><name><surname>Bassaganyas</surname><given-names>L</given-names></name><name><surname>Baumann</surname><given-names>T</given-names></name><name><surname>Juan</surname><given-names>M</given-names></name><name><surname>López-Guerra</surname><given-names>M</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Tubío</surname><given-names>JM</given-names></name><name><surname>López</surname><given-names>C</given-names></name><name><surname>Navarro</surname><given-names>A</given-names></name><name><surname>Tornador</surname><given-names>C</given-names></name><name><surname>Aymerich</surname><given-names>M</given-names></name><name><surname>Rozman</surname><given-names>M</given-names></name><name><surname>Hernández</surname><given-names>JM</given-names></name><name><surname>Puente</surname><given-names>DA</given-names></name><name><surname>Freije</surname><given-names>JM</given-names></name><name><surname>Velasco</surname><given-names>G</given-names></name><name><surname>Gutiérrez-Fernández</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Carrió</surname><given-names>A</given-names></name><name><surname>Guijarro</surname><given-names>S</given-names></name><name><surname>Enjuanes</surname><given-names>A</given-names></name><name><surname>Hernández</surname><given-names>L</given-names></name><name><surname>Yagüe</surname><given-names>J</given-names></name><name><surname>Nicolás</surname><given-names>P</given-names></name><name><surname>Romeo-Casabona</surname><given-names>CM</given-names></name><name><surname>Himmelbauer</surname><given-names>H</given-names></name><name><surname>Castillo</surname><given-names>E</given-names></name><name><surname>Dohm</surname><given-names>JC</given-names></name><name><surname>de Sanjosé</surname><given-names>S</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>de Alava</surname><given-names>E</given-names></name><name><surname>San Miguel</surname><given-names>J</given-names></name><name><surname>Royo</surname><given-names>R</given-names></name><name><surname>Gelpí</surname><given-names>JL</given-names></name><name><surname>Torrents</surname><given-names>D</given-names></name><name><surname>Orozco</surname><given-names>M</given-names></name><name><surname>Pisano</surname><given-names>DG</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Bayés</surname><given-names>M</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Gut</surname><given-names>M</given-names></name><name><surname>Klatt</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Stebbings</surname><given-names>LA</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>López-Guillermo</surname><given-names>A</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia</article-title><source>Nature</source><volume>475</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature10113</pub-id><pub-id pub-id-type="pmid">21642962</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveh</surname><given-names>B</given-names></name><name><surname>London</surname><given-names>N</given-names></name><name><surname>Zimmerman</surname><given-names>L</given-names></name><name><surname>Schueler-Furman</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Rosetta flexpepdock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors</article-title><source>PLoS One</source><volume>6</volume><elocation-id>e18934</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018934</pub-id><pub-id pub-id-type="pmid">21572516</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>SA</given-names></name><name><surname>Lounsbury</surname><given-names>KM</given-names></name><name><surname>Carey</surname><given-names>KL</given-names></name><name><surname>Macara</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A nuclear export signal is essential for the cytosolic localization of the ran binding protein, RanBP1</article-title><source>The Journal of Cell Biology</source><volume>134</volume><fpage>1157</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1083/jcb.134.5.1157</pub-id><pub-id pub-id-type="pmid">8794858</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuermann</surname><given-names>TH</given-names></name><name><surname>Padrick</surname><given-names>SB</given-names></name><name><surname>Gardner</surname><given-names>KH</given-names></name><name><surname>Brautigam</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>On the acquisition and analysis of microscale thermophoresis data</article-title><source>Analytical Biochemistry</source><volume>496</volume><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2015.12.013</pub-id><pub-id pub-id-type="pmid">26739938</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>CE</given-names></name><name><surname>de Vries</surname><given-names>SJ</given-names></name><name><surname>Zacharias</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Fully blind Peptide-Protein docking with pepATTRACT</article-title><source>Structure</source><volume>23</volume><fpage>1507</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.05.021</pub-id><pub-id pub-id-type="pmid">26146186</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>MG</given-names></name><name><surname>Le Rouzic</surname><given-names>E</given-names></name><name><surname>Périanin</surname><given-names>A</given-names></name><name><surname>Pierotti</surname><given-names>V</given-names></name><name><surname>Enslen</surname><given-names>H</given-names></name><name><surname>Benichou</surname><given-names>S</given-names></name><name><surname>Marullo</surname><given-names>S</given-names></name><name><surname>Benmerah</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential nucleocytoplasmic shuttling of beta-arrestins. characterization of a leucine-rich nuclear export signal in beta-arrestin2</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>37693</fpage><lpage>37701</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207552200</pub-id><pub-id pub-id-type="pmid">12167659</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stade</surname><given-names>K</given-names></name><name><surname>Ford</surname><given-names>CS</given-names></name><name><surname>Guthrie</surname><given-names>C</given-names></name><name><surname>Weis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Exportin 1 (Crm1p) is an essential nuclear export factor</article-title><source>Cell</source><volume>90</volume><fpage>1041</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80370-0</pub-id><pub-id pub-id-type="pmid">9323132</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>YT</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Acharya</surname><given-names>C</given-names></name><name><surname>Calle</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>MY</given-names></name><name><surname>Cea</surname><given-names>M</given-names></name><name><surname>Tannenbaum</surname><given-names>D</given-names></name><name><surname>Cagnetta</surname><given-names>A</given-names></name><name><surname>Reagan</surname><given-names>M</given-names></name><name><surname>Munshi</surname><given-names>AA</given-names></name><name><surname>Senapedis</surname><given-names>W</given-names></name><name><surname>Saint-Martin</surname><given-names>JR</given-names></name><name><surname>Kashyap</surname><given-names>T</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Ghobrial</surname><given-names>I</given-names></name><name><surname>Zhan</surname><given-names>F</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Schey</surname><given-names>SA</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications</article-title><source>Leukemia</source><volume>28</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/leu.2013.115</pub-id><pub-id pub-id-type="pmid">23588715</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakar</surname><given-names>K</given-names></name><name><surname>Karaca</surname><given-names>S</given-names></name><name><surname>Port</surname><given-names>SA</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Kehlenbach</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of CRM1-dependent nuclear export cargos using quantitative mass spectrometry</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>12</volume><fpage>664</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1074/mcp.M112.024877</pub-id><pub-id pub-id-type="pmid">23242554</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tidow</surname><given-names>H</given-names></name><name><surname>Nissen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural diversity of calmodulin binding to its target sites</article-title><source>FEBS Journal</source><volume>280</volume><fpage>5551</fpage><lpage>5565</lpage><pub-id pub-id-type="doi">10.1111/febs.12296</pub-id><pub-id pub-id-type="pmid">23601118</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrance</surname><given-names>GM</given-names></name><name><surname>Leader</surname><given-names>DP</given-names></name><name><surname>Gilbert</surname><given-names>DR</given-names></name><name><surname>Milner-White</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A novel main chain motif in proteins bridged by cationic groups: the niche</article-title><source>Journal of Molecular Biology</source><volume>385</volume><fpage>1076</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.11.007</pub-id><pub-id pub-id-type="pmid">19038265</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trellet</surname><given-names>M</given-names></name><name><surname>Melquiond</surname><given-names>AS</given-names></name><name><surname>Bonvin</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A unified conformational selection and induced fit approach to protein-peptide docking</article-title><source>PLoS One</source><volume>8</volume><elocation-id>e58769</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0058769</pub-id><pub-id pub-id-type="pmid">23516555</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>F</given-names></name><name><surname>Maru</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>8867</fpage><lpage>8872</lpage><pub-id pub-id-type="doi">10.1074/jbc.M308848200</pub-id><pub-id pub-id-type="pmid">14684748</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vercruysse</surname><given-names>T</given-names></name><name><surname>De Bie</surname><given-names>J</given-names></name><name><surname>Neggers</surname><given-names>JE</given-names></name><name><surname>Jacquemyn</surname><given-names>M</given-names></name><name><surname>Vanstreels</surname><given-names>E</given-names></name><name><surname>Schmid-Burgk</surname><given-names>JL</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Baloglu</surname><given-names>E</given-names></name><name><surname>Landesman</surname><given-names>Y</given-names></name><name><surname>Senapedis</surname><given-names>W</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Dagklis</surname><given-names>A</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><name><surname>Daelemans</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia</article-title><source>Clinical Cancer Research</source><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1580</pub-id><pub-id pub-id-type="pmid">27780859</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Meinkoth</surname><given-names>JL</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Identification of a signal for rapid export of proteins from the nucleus</article-title><source>Cell</source><volume>82</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90435-2</pub-id><pub-id pub-id-type="pmid">7634336</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><name><surname>Collett</surname><given-names>G</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Sequence and structural analyses of nuclear export signals in the NESdb database</article-title><source>Molecular Biology of the Cell</source><volume>23</volume><fpage>3677</fpage><lpage>3693</lpage><pub-id pub-id-type="doi">10.1091/mbc.E12-01-0046</pub-id><pub-id pub-id-type="pmid">22833565</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><name><surname>Collett</surname><given-names>G</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2012">2012c</year><article-title>Sequence and structural analyses of nuclear export signals in the NESdb database</article-title><source>Molecular Biology of the Cell</source><volume>23</volume><fpage>3677</fpage><lpage>3693</lpage><pub-id pub-id-type="doi">10.1091/mbc.E12-01-0046</pub-id><pub-id pub-id-type="pmid">22833565</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>NESdb: a database of NES-containing CRM1 cargoes</article-title><source>Molecular Biology of the Cell</source><volume>23</volume><fpage>3673</fpage><lpage>3676</lpage><pub-id pub-id-type="doi">10.1091/mbc.E12-01-0045</pub-id><pub-id pub-id-type="pmid">22833564</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Marquis</surname><given-names>K</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>SC</given-names></name><name><surname>Cağatay</surname><given-names>T</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Chook</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins</article-title><source>Bioinformatics</source><volume>31</volume><fpage>1357</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu826</pub-id><pub-id pub-id-type="pmid">25515756</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fully blind docking at the atomic level for Protein-Peptide complex structure prediction</article-title><source>Structure</source><volume>24</volume><fpage>1842</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.07.021</pub-id><pub-id pub-id-type="pmid">27642160</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>DeLisi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Structural principles that govern the peptide-binding motifs of class I MHC molecules</article-title><source>Journal of Molecular Biology</source><volume>281</volume><fpage>929</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1998.1982</pub-id><pub-id pub-id-type="pmid">9719645</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.23961.045</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Mingjie</given-names></name><role>Reviewing editor</role><aff id="aff3"><institution>The Hong Kong University of Science and Technology</institution>, <country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;CRM1 recognizes diverse Nuclear Export Signals conformations&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and John Kuriyan as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Gino Cingolani (Reviewer #1) and Douglas Barrick (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This &quot;Research Advances&quot; manuscript describes continued structural analysis of NES sequences bound to CRM1, a nuclear export receptor. In the previous 2015 <italic>eLife</italic> paper, the authors published two crystal structures of bound sequences and showed that they can interact in different ways, reversing chain orientation. In the present study, they solve eight additional structures from diverse sequences, and characterize additional variation in the mode of binding. The results demonstrate that a 'folded' secondary structure is not a prerequisite to bear a functional NES. Instead, sidechains from the NES sequences arranged in conformations that match the tight and restrained groove generated at the HEAT:HEAT interface are the key determinants. The results help to define different sequence motifs for binding, and how they translate into structure. The present study is certainly an advance from the previous work. As such, the manuscript is favorable for the format of &quot;Research Advances&quot; in <italic>eLife</italic>.</p><p>Essential revisions:</p><p>1) One major comment to be addressed in revision is that the authors should do a better job in <xref ref-type="fig" rid="fig1">Figure 1</xref> showing the sequences in each NES subfamily, their expected structures, and their actual structures (perhaps a string of h's, s's, and t's). And importantly, indicate which sequences are from the current study, and which are from previous studies. Without a better guide, most readers won't remember which NES sequence has which structure, sequence motif, and orientation.</p><p>2) Although all of the crystal structures are solved at a resolution ranging from 2.0~2.5 Å, the electron densities for some of the NES peptides may not have sufficient quality for reliably model building (some of the sidechain densities for the critical hydrophobic residues are missing, e.g. FMRP-1b, mDia-2, etc.). The overall statistics (R factor and R-free factor) cannot reflect this because the peptide only constitutes a small portion of the entire structure. Moreover, the B factors for some of the peptides are extremely high compared to the CRM1*-Ran-RanBP1 protein, suggesting overfitting of the peptides to some extent. The authors need to address this point by stating the rationales for modelling the peptides as they reported.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.23961.046</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic> </p><p><italic>1) One major comment to be addressed in revision is that the authors should do a better job in <xref ref-type="fig" rid="fig1">Figure 1</xref> showing the sequences in each NES subfamily, their expected structures, and their actual structures (perhaps a string of h's, s's, and t's). And importantly, indicate which sequences are from the current study, and which are from previous studies. Without a better guide, most readers won't remember which NES sequence has which structure, sequence motif, and orientation.</italic> </p><p>To better show the sequence patterns of each NES subfamily, we changed the font in <xref ref-type="fig" rid="fig1">Figure 1A</xref> of the manuscript to the monospace Courier New font. To incorporate information about potential α-helices within consensus sequences of the different NES classes or subfamily, we shaded these regions grey. These regions of the NESs are predicted to be amphipathic α-helices because their hydrophobic residues form patterns of <italic>i, i</italic>+4, <italic>i</italic>+7 or <italic>i, i</italic>+3, <italic>i</italic>+7 or <italic>i, i</italic>+3, <italic>i</italic>+7, <italic>i</italic>+10. This explanation of how we predict α-helical parts of NESs is now included in 1) the legend for <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">2</xref>) the revised Introduction where we added new text to better explain the unexpected previously solved structures of CRM1-bound hRio2<sup>NES</sup> and CPEB4<sup>NES</sup> which has the potentially all-helical class 3 pattern, and 3) the Results section where we revised the text to include rationale for the potentially non-helical class 2 and class 1b NESs.</p><p>We also added information into <xref ref-type="fig" rid="fig1">Figure 1B, D-F</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref> of the manuscript so that they can serve as better guides to clearly distinguish previous structures from new structures, and connect sequence motifs with peptide structure/orientation:</p><p>1) We added prominently displayed PDB IDs to the structures in <xref ref-type="fig" rid="fig1">Figure 1B</xref> of the manuscript to clearly indicate that all three peptides are previously published structures.</p><p>2) In <xref ref-type="fig" rid="fig1">Figure 1B</xref>, we also added the sequence of each NES and their respective NES class, marked Φ0-Φ4 residues in the sequences and labeled one Φ residue of each peptide structure to connect the structures to the sequences.</p><p>3) In <xref ref-type="fig" rid="fig1">Figure 1D-F</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>, we clearly indicated the NES class or subfamily for each NES peptide, marked the Φ0-Φ4 residues in the sequences, and one Φ residue in each peptide structure.</p><p>Changes in the text of the manuscript:</p><p>We revised the legend for <xref ref-type="fig" rid="fig1">Figure 1</xref> according to the changes above: “(A) NES sequence patterns (Φ is Leu, Val, Ile, Phe or Met and X is any amino acid). Potential amphipathic α-helices, predicted with hydrophobic patterns of <italic>i, i</italic>+4, <italic>i</italic>+7 or <italic>i, i</italic>+3, <italic>i</italic>+7 or <italic>i, i</italic>+3, <italic>i</italic>+7, <italic>i</italic>+10, are shaded grey.”</p><p>We also revised text in the Introduction and Results of the manuscript. The revised text in Introduction reads: “Previously, we studied NESs with the Φ1XXΦ2XXXΦ3XXΦ4 (class 3) pattern where the <italic>i, i</italic>+3, <italic>i</italic>+7, <italic>i</italic>+10 Φ positions suggested a single long amphipathic helix. […] Structures of such NESs from kinase RIO2 and cytoplasmic polyadenylation element-binding protein 4 (hRio2<sup>NES</sup>, CPEB4<sup>NES</sup>) showed that they do not adopt all-helical conformations but unexpectedly adopt helix-strand conformations that bind CRM1 in the opposite or minus (-) polypeptide direction to that of SNUPN<sup>NES</sup>, PKI<sup>NES</sup> and Rev<sup>NES</sup> ((+) NESs) (16).”</p><p>The revised text in Results reads: “We study three NESs that uniquely match the all-helical class 3 pattern (Ф1XXФ2XXXФ3XXФ4). Because most previously studied NESs have substantial helical content, we also study five NESs that match class 2 (Ф1XФ2XXФ3XФ4) and class 1b (Ф1XXФ2XXФ3XФ4) patterns, where the hydrophobic residue positions do not suggest an amphipathic helix (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).”</p><p><italic>2) Although all of the crystal structures are solved at a resolution ranging from 2.0~2.5 Å, the electron densities for some of the NES peptides may not have sufficient quality for reliably model building (some of the sidechain densities for the critical hydrophobic residues are missing, e.g. FMRP-1b, mDia-2, etc.). The overall statistics (R factor and R-free factor) cannot reflect this because the peptide only constitutes a small portion of the entire structure. Moreover, the B factors for some of the peptides are extremely high compared to the CRM1*-Ran-RanBP1 protein, suggesting overfitting of the peptides to some extent. The authors need to address this point by stating the rationales for modelling the peptides as they reported.</italic> </p><p>We thank the reviewers for pointing out the need to provide clear rationale for the way we modeled the NES peptides. As they noted, densities are missing for the Φ1 and Φ3 side chains of mDia2<sup>NES</sup> and for the Φ1 side chain of FMRP-1b<sup>NES</sup>.</p><p>To model the bound mDia2<sup>NES</sup> peptide (sequence: GGSY-<sup>1179</sup>SVPEVEALLARLRAL<sup>1193</sup>), we made use of the obvious electron densities (mFo-DFc map) for long side chains to guide sequence assignment. There is strong side chain density suitable for an arginine side chain on the peptide (white dashed circle in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). There are only two arginine residues in the mDia2<sup>NES</sup> peptide, Arg1189 and Arg1191. If the long side chain density is assigned to Arg1189, then Arg1191 would end up pointing into the binding groove – a very energetically unfavorable and unlikely situation. Furthermore, Ala1188 would end up in the P2 pocket of CRM1 where there is obvious density for a longer hydrophobic side chain (left panel of <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). On the other hand, when Arg1191 is assigned to the long and continuous side chain density (adjacent to helix H12A of CRM1), the remaining side chains in the NES end up in positions that are consistent the electron densities.</p><p>For the FMRP-1b<sup>NES</sup> (sequence: <sup>1</sup>GGS-YLKEVDQLRALERLQID<sup>20</sup>), there are no obvious long side chain densities that could help with modeling. There are however obvious densities for several side chains in the first two turn of the NES helix. These side chain densities are consistent with two possible sequence assignments: <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup> or the more C-terminal <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup>. We tested modeling of FMRP-1b<sup>NES</sup> by refining both peptide models and by testing a mutant peptide that should distinguish between the two models. Ten cycles of PHENIX refinement of the <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup> model resulted in positive and negative difference densities (mFo-DFc map) at several NES side chains, which suggested an incorrect assignment (left panels, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). In contrast, difference densities are absent when the <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> model is refined (right panels, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). The final FMRP-1b<sup>NES</sup> structure was therefore modelled as <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup>.</p><p>The sequence assignment of FMRP-1b<sup>NES</sup> was also tested in an additional experiement using a mutant FMRP-1b<sup>NES</sup> that has the sequence YLKEVDQLRALER. If the NES is <sup>5</sup><underline>L</underline>KE<underline>V</underline>DQ<underline>L</underline>R<underline>A</underline>L<sup>14</sup>, FMRP-1b<sup>NES</sup> mutant YLKEVDQLRALER should bind well to CRM1. However, if <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> is the FMRP-1b<sup>NES</sup>, mutant YLKEVDQLRALER should not bind CRM1 as the C-terminal half of the NES or <sup>17</sup><underline>L</underline>Q<underline>I</underline>D<sup>20</sup> which includes Ф3 and Ф4 is missing. New experimental results in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> show that FMRP-1b<sup>NES</sup> mutant YLKEVDQLRALER does not bind CRM1, providing further support that the NES is indeed <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> as currently assigned.</p><p>We also agree with the reviewers that B-factors of the NES peptides, which are mostly between 60-90 Å2, with the expection of CDC7<sup>NES</sup>-ext and Hxk2<sup>pep</sup> at 90-100 Å2, are high compared to the overall average B-factors for the proteins in the crystalsin all structures). We examined the average B-factors for 29 CRM1 residues that line the NES groove, and noticed that they are in the 50-70 Å2 range, higher than average B-factors for the rest of CRM1 but lower than NES B-factors. The high NES B-factors are likely due to partial occupancy of the NES peptides in the CRM1 grooves. Our peptide models remain reliable despite high B-factors as kick OMIT densities calculated with NES peptides omitted clearly show presence of the NES peptides and the omit densities also match the final peptide models well (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>Changes in the text of the manuscript:</p><p>We added a sentence in main text of the manuscript (Results section) to refer to the Methods section for details on our modeling strategy: “All eight NESs bind <italic><sup>Hs</sup></italic>CRM1 in the presence of RanGTP with dissociation constants (K<sub>D</sub>s) of 670 nM-20 μM, and were crystallized bound to the previously described engineered <italic><sup>Sc</sup></italic>CRM1-RanGppNHp-Yrb1p complex (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Figure 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="SD2-data">2</xref>, <xref ref-type="supplementary-material" rid="SD3-data">3</xref>) (Xu et al., 2012). Details of how the NES peptides were modelled can be found in the Methods section and in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="fig" rid="fig1s3">3</xref>.”</p><p>We also added the following description of how peptides are modeled to the Methods section:</p><p>“NES peptides are modeled according to the positive difference density (2mFo-DFc map) at the binding groove after refinement of the CRM1-Ran-RanBP1 model. […] Results in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> show that FMRP-1b<sup>NES</sup> mutant YLKEVDQLRALER does not bind CRM1, providing further support that the NES is indeed <sup>11</sup><underline>L</underline>RA<underline>L</underline>ER<underline>L</underline>Q<underline>I</underline>D<sup>20</sup> as currently assigned.”</p></body></sub-article></article>